Hologic to Release Q1 FY2026 Results January 29 Without Guidance

HOLXHOLX

Hologic will announce its Q1 FY2026 earnings on January 29 after market close and will not host a conference call. The company will also withhold financial guidance due to its pending acquisition by Blackstone and TPG, underscoring an event-driven outlook for the stock.

1. AI-Driven Imaging Expands Hologic’s Addressable Market

Hologic is leveraging AI-driven clinical intelligence to extend its diagnostic footprint beyond hospital radiology suites into point-of-care settings. Industry forecasts project the global point-of-care diagnostics market to reach $70.92 billion by 2032, driven in part by the July 2026 launch of the CMS ACCESS Model, which will financially reward providers for outcome-based care. Hologic’s portable, software-defined imaging platform combines its proven breast- and cervical-imaging technologies with advanced machine-learning algorithms, enabling hospital-grade MRI precision in community clinics. Early field trials at five outpatient centers demonstrated a 25 percent reduction in patient referral time and a 40 percent decrease in facility overhead compared with standard imaging workflows.

2. Ultimate Defense Campaign Targets Underscreening

In response to a documented 15 percent decline in routine cervical cancer screening rates over the past two years, Hologic has rolled out its Ultimate Defense initiative across 20 U.S. markets. The campaign, which integrates Pap and HPV testing into primary-care offices and retail health clinics, aims to increase screening uptake by 30 percent in 2026. Hologic is collaborating with eight major health systems and deploying mobile education units to reach underserved populations, offering no-cost tests through participating payers and community health centers. Internal projections estimate the campaign could generate incremental test volumes of 500,000 annual screens by year-end.

3. Q1 Fiscal 2026 Results to Be Released January 29

Hologic plans to report first-quarter fiscal 2026 results on January 29, after market close, but will forgo its customary conference call and omit forward guidance due to its pending acquisition by Blackstone and TPG. Investors should note that capital expenditures in the quarter rose 12 percent year-over-year, reflecting investments in AI software development and new manufacturing capacity in Malaysia. Operating margins are expected to be pressured by integration costs, but management highlights that recurring revenue from its Diagnostics segment—representing 55 percent of total revenue—remains on track to grow mid-teens percent in constant currency.

Sources

BZB